Resources

 

Fact Sheets

Document: CSRxP Letter to Senate Finance Committee

The Campaign for Sustainable Rx Pricing (CSRxP) wishes to commend you for your strong bipartisan efforts to lower prescription drug prices for Americans by moving forward with the U.S. Senate Committee on Finance package on drug pricing. CSRxP believes that the Senate Finance package is a good first step in slowing the unsustainable growth

07-24-2019

Document: Restructuring the CMS Federal Reinsurance Program to Include Manufacturer Liability

As prescription drug prices continue to rise, many stakeholders have debated how to slow the trend and who should pay for it. The Medicare Advantage and Part D programs remain at the center of this discussion. Organizations such as the Medicare Payment Advisory Commission (“MedPAC”) and the American Action Form (“AAF”) as well as

06-24-2019

Document: USMCA Letter

The Campaign for Sustainable Rx Pricing (CSRxP) is a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists and businesses — promoting bipartisan, market-based solutions to lower drug prices in America. We appreciate the bipartisan attention and activity that lawmakers in Congress have placed on tackling the crisis of rising

06-18-2019

Fact Sheet: Big Pharma: Investing Boldly in Advertising and Profits, Not R&D

Drug prices are out of control. But Big Pharma is posting record profits. Where is all that money going? Not research and development. For the top ten U.S. companies, nearly 80% of every Big Pharma dollar goes to something other than R&D.¹

05-14-2019

Final Comment Letter: Proposed Rebate Rule

Despite efforts from the brand drug industry to suggest otherwise, brand pharmaceutical companies – and pharmaceutical companies alone – are the drivers of the high drug prices American consumers and taxpayers face every day. Brand manufacturers set unsustainably high launch prices for their products and typically increase those prices at rates that far exceed

04-8-2019

Drug Pricing Overview: 116th Congress

On behalf of the Campaign for Sustainable Rx Pricing (CSRxP), a nonpartisan coalition of doctors, physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, patient advocates and businesses committed to lowering drug prices, congratulations on being elected to represent your constituents in the 116th Congress. Our organization believes no one should ever have to choose

01-30-2019

Fact Sheet: The Facts About Rising Drug Prices

Drug prices in the United States are too high and continue to skyrocket. The unsustainable cost of prescription drugs not only puts pressure on the health care system but increasingly; patients, employers, and providers are paying prices that are too high.

01-6-2019

Fact Sheet: Proposals for Change – Detailed

The current market for pricing drugs in the United States is broken, and it’s unsustainable for American businesses, families, and our economy. Today, prescription drug expenditures make up nearly 20 percent of all health care costs, and prescription spending is growing faster than any other part of the health care dollar.

01-6-2019

Fact Sheet: CSRxP Proposals for Change – Summary

Drug prices in the United States are too high and sharply rising prescription drug prices threaten the affordability of health care and the vitality of our entire economy. CSRxP has developed market-based reforms that restore a functioning market by increasing transparency, promoting competition and innovation, and that result in value.

12-21-2018

Document: CSRxP Comment Letter – CMS-4187-P

Dear Administrator Verma: The Campaign for Sustainable Rx Pricing (CSRxP) is a nonpartisan coalition of organizations committed to fostering an informed discussion on sustainable drug pricing and developing bipartisan, market-based solutions that promote competition, transparency, and value to improve affordability while maintaining patient access to innovative prescription drugs that can improve health outcomes and

12-17-2018

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.